Barclays PLC Geron Corp Call Options Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $45,674 - $54,450	22,500 New	22,500 $54,000
Q2 2020 Aug 12, 2020	SELL	$1.05 - $2.18 $184,170 - $382,372	-175,400 Reduced 99.77%	400 $1,000
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $143,968 - $521,884	81,800 Added 87.02%	175,800 $310,000
Q1 2018 May 15, 2018	BUY	$1.81 - $5.98 $163,262 - $539,396	90,200 Added 2373.68%	94,000 $400,000
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $7,562 - $10,070	3,800	3,800 $8,000

306

465M

1.07M

648K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $895M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.